Seaport Therapeutics SPTX
Drug Manufacturers - General, Healthcare
$20.01
+2.09%
- Market cap
- $1.1B
- PE
- n/m
- one or more of the four quarters through 2026-09-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| R&D | $10.5M | $13.4M | $20.5M | $21.4M | $24.6M | $23.9M |
| SG&A | $5.7M | $5.1M | $5M | $6.1M | $41.2M | $6.5M |
| −$16.2M | −$18.5M | −$25.4M | −$27.5M | −$65.8M | −$30.3M | |
| Pre-tax income | −$13.1M | −$14.9M | −$22.4M | −$24.9M | −$62.3M | −$26.3M |
| $31K | $134K | $95K | $519K | $251K | $127K | |
| Net income | −$13.1M | −$15.1M | −$22.5M | −$25.4M | −$62.6M | −$26.4M |
| −$5.65 | −$6.40 | −$9.43 | −$10.34 | −$1.78 | −$0.49 | |
| 2.3M | 2.4M | 2.4M | 2.5M | 35.2M | 53.5M |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Seaport Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SPTXSeaport Therapeutics | $1.1B | n/m | n/a | n/m | n/m | n/m | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.7× | 1.9× | +6% | 2.0% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANIPANI Pharmaceuticals | $1.6B | 15.0× | 57.5× | 1.7× | +31% | 11.1% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| Peer median | $1.2B | 13.4× | 19.8× | 1.6× | +17% | 10.9% |
More on Seaport Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .